Inocras closes $31 million in Series B-3 financing to accelerate U.S. commercial expansion.
Amount Raised
$31 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareGeneticsDescription
Inocras has successfully closed an oversubscribed Series B-3 financing round, raising $31 million. This funding will be utilized to support the company's commercial expansion efforts in the U.S. market. The round demonstrates strong investor confidence in Inocras's growth strategy and potential.
Quick answer
Inocras & Summit Pharmaceuticals International Corporation raised $31 Million in a Series B round, dated August 3, 2026. Inocras & Summit Pharmaceuticals International Corporation is based in San Diego, California, United States.
- How much did Inocras & Summit Pharmaceuticals International Corporation raise?
- Inocras & Summit Pharmaceuticals International Corporation raised $31 Million in a Series B round on August 3, 2026.
- What does Inocras & Summit Pharmaceuticals International Corporation do?
- Inocras Inc. and Summit Pharmaceuticals International Corporation are collaborating to bring advanced whole genome sequencing (WGS) and bioinformatics services to Japan's healthcare system, aiming to better understand..
- Where is Inocras & Summit Pharmaceuticals International Corporation based and how big is it?
- Inocras & Summit Pharmaceuticals International Corporation is based in San Diego, California, United States. Fundz records about 72 employees.
- Who are the decision-makers at Inocras & Summit Pharmaceuticals International Corporation?
- Fundz holds 2 contacts at Inocras & Summit Pharmaceuticals International Corporation, including the Chief Commercial Officer (CCO). Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Biotechnology around the same time
Companies in the same sectors as Inocras & Summit Pharmaceuticals International Corporation that raised within 45 days of this round, from Fundz verified event records.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- Epicrispr Biotechnologies raised $90M (Series C) on August 10, 2026.
- GenePlanet raised an undisclosed amount (Private Equity) on July 31, 2026.
- Decode Health raised $1.9M (Grant) on July 14, 2026.
- Grail raised $110M (Post-IPO Equity) on June 25, 2026.
- Matisse Pharmaceuticals B.V raised $16M (Series A) on September 17, 2026.
Who to call at Inocras & Summit Pharmaceuticals International Corporation, and when
A new round usually means Inocras & Summit Pharmaceuticals International Corporation is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Inocras & Summit Pharmaceuticals International Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Inocras & Summit Pharmaceuticals International Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Inocras & Summit Pharmaceuticals International Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Inocras & Summit Pharmaceuticals International Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansInocras & Summit Pharmaceuticals International Corporation raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.